Context Therapeutics (CNTX) Shares Outstanding (Weighted Average) (2020 - 2026)

Context Therapeutics has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $95.2 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $95.2 million, up 739.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $95.2 million (up 739.16% YoY), and the FY2025 annual result was $95.2 million, up 739.18% from the prior year.
• Shares Outstanding (Weighted Average) came in at $95.2 million for Q1 2026 at Context Therapeutics, roughly flat from $95.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $95.2 million in Q4 2025 to a low of $5.9 million in Q1 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $16.0 million (2022), against an average of $33.3 million.
• Across the five-year window, Shares Outstanding (Weighted Average) soared 4471.72% in 2022 and sank 68.01% in 2025, its largest moves.
• Context Therapeutics' Shares Outstanding (Weighted Average) stood at $16.0 million in 2022, then changed by 0.0% to $16.0 million in 2023, then soared by 265.88% to $58.4 million in 2024, then soared by 62.94% to $95.2 million in 2025, then retreated by 0.0% to $95.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $95.2 million (Q1 2026), $95.2 million (Q4 2025), and $95.2 million (Q3 2025), per Business Quant data.